APELLIS PHARMACEUTICALS INC (APLS) Stock Analyst Ratings
USA - NASDAQ:APLS - US03753U1060 - Common Stock
20.19 USD
+0.17 (+0.85%)
ChartMill assigns a Buy % Consensus number of 79% to APLS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 38.7. This target is 91.7% above the current price.
APLS was analyzed by 27 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about APLS.
In the previous month the buy percentage consensus was at a similar level.
APLS was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | Wolfe Research | Initiate | Peer Perform |
| 2025-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-03 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-10-31 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-31 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-31 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-15 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-09-26 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2025-08-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-01 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-01 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-08-01 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-08-01 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-16 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-07-02 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-02 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-22 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-14 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-05-09 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-05-09 | B of A Securities | Downgrade | Buy -> Neutral |
| 2025-05-08 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-05-08 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-05-08 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-08 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-21 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
APELLIS PHARMACEUTICALS INC / APLS FAQ
What do analysts expect the price target to be for APELLIS PHARMACEUTICALS INC (APLS)?
27 analysts have analysed APLS and the average price target is 38.7 USD. This implies a price increase of 91.7% is expected in the next year compared to the current price of 20.19.
Can you provide the consensus rating for APELLIS PHARMACEUTICALS INC stock?
The consensus rating for APELLIS PHARMACEUTICALS INC (APLS) is 78.5185 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed APELLIS PHARMACEUTICALS INC (APLS)?
The number of analysts covering APELLIS PHARMACEUTICALS INC (APLS) is 27.